~~Table~~ UNITED ofSTATES SECURITIES ~~Contents~~AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

~~UNITED STATES~~ ~~SECURITIES~~ FORM ~~AND EXCHANGE COMMISSION~~8-K

~~Washington,~~ CURRENT ~~D.C. 20549~~REPORT

~~FORM~~ Pursuant ~~8-K~~to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~CURRENT~~Date ~~REPORT Pursuant~~of toReport ~~Section 13 OR 15~~(d)Date of ~~The~~ ~~Securities~~Earliest ~~Exchange~~Event ~~Act~~Reported): ofNovember ~~1934~~ 5, 2007

~~Date~~ Encysive ofPharmaceuticals ~~Report~~ Inc. __________________________________________ (~~Date~~Exact name of ~~earliest~~registrant ~~event~~as ~~reported):~~specified ~~November 5,~~in ~~2007~~its charter)

Encysive Pharmaceuticals Inc.


Delaware	0-20117	13-3532643
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)

4848 Loop Central Drive, Suite 700, Houston, Texas		77081
_________________________________ (Address of principal executive offices)		___________ (Zip Code)

~~(Exact~~Registrant’s ~~name~~telephone ofnumber, ~~registrant~~including asarea ~~specified~~code: ~~in its charter)~~713-796-8822

Delaware	0-20117	13-3532643
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)
4848 Loop Central Drive, Suite 700, Houston, Texas		77081
(Address of principal executive offices)		(Zip Code)

Not Applicable
______________________________________________
Former name or former address, if changed since last report

~~Registrant’s~~ Check ~~telephone~~the ~~number,~~appropriate ~~including~~box ~~area~~below ~~code:~~if ~~713~~the Form 8-~~796-8822~~K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

~~Not~~ [ ] Written ~~Applicable~~communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~(Former~~ Top ~~name~~of orthe ~~former address, if changed since last report.)~~Form

~~Check~~ Item ~~the appropriate box below if the Form~~ 8-K.01 ~~filing~~Other ~~is intended to simultaneously satisfy the~~Events. ~~filing obligation of the registrant under any of the following provisions (see General Instruction~~ ~~A.2. below):~~

o On ~~Written~~November ~~communications~~5, ~~pursuant~~2007, Encysive Pharmaceuticals Inc. (the "Company") announced that open label observational data from Columbia University suggests that sitaxsentan (Thelin™), a selective endothelin A receptor antagonist, may improve symptoms associated with Eisenmenger syndrome (ES). The analyses were presented on November 5, 2007 at the American Heart Association (AHA) Scientific Sessions 2007 meeting in Orlando.A retrospective chart review was performed on 14 consecutive ES patients (10 females, 4 males; age 27 ± 11 years) initiating open label sitaxsentan therapy (100 mg tablets daily) at Columbia University between 2002 and 2006. Baseline data were compared to ~~Rule 425~~short- ~~under~~and long-term follow-up data at 12 weeks and at approximately one year. There was a significant decrease in the ~~Securities~~pulmonary ~~Act~~vascular resistance (17PVR) ~~CFR~~to ~~230~~systemic vascular resistance (SVR) ratio, consistent with pulmonary selectivity in these patients.~~425~~ The improvements in PVR index and six-minute walk distance were not significant. During the one-year follow-up, these ES patients had no significant change in resting systemic arterial oxygen saturation. About Eisenmenger SyndromeEisenmenger syndrome is a progressive cardiovascular condition that can develop in individuals who have un-repaired congenital heart defects. ES is initially associated with increased pulmonary blood pressure that, if the congenital heart defect(s) is not repaired, results in reversal of the shunt from left to right to right to left with progressive pulmonary vascular disease and progressive cyanosis. ES is linked to multi-organ damage and premature death. There is currently no cure for ES once it is established.

oThis ~~Soliciting~~current ~~material~~report ~~pursuant~~on toForm ~~Rule 14a~~8-12K ~~under~~contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act ~~(17~~of ~~CFR~~1934, ~~240~~as amended.~~14a~~ These forward-12looking statements are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are decisions by the U.S. Food and Drug Administration regarding whether and when to approve our drug application for THELIN™ (sitaxsentan sodium) , our ability to raise capital to fund cash requirements for future operations, timelines for initiating new trials and completing ongoing clinical trials for sitaxsentan sodium (THELIN™), our estimates of the sufficiency of our existing capital resources, as well as more specific risks, trends and uncertainties facing Encysive such as those set forth in its reports on Forms 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks, trends and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore you should not rely on any such forward-looking statements. Furthermore, Encysive undertakes no duty to update or revise these forward-looking statements. The Private Securities Litigation Reform Act of 1995 permits this discussion.

o Top ~~Pre-commencement~~of ~~communications pursuant to Rule 14d-2(b) under~~ the ~~Exchange Act (17 CFR~~Form ~~240.14d-2(b))~~

~~o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR~~ ~~240.13e-4(c))~~ SIGNATURES

~~TABLE~~ Pursuant OFto ~~CONTENTS~~the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Item 7.01. Regulation FD Disclosure Item 9.01. Financial Statements and Exhibits SIGNATURES Presentation


	Encysive Pharmaceuticals Inc.

November 5, 2007	By:	/s/ Paul S. Manierre

		Name: Paul S. Manierre
		Title: Vice President, General Counsel and Secretary

Item 7.01. Regulation FD Disclosure.

In accordance with General Instruction B.2. of Form 8-K, the information presented under this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Representatives of Encysive Pharmaceuticals Inc. (the “Company”) intend to make presentations beginning on Monday, November 5, 2007, at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference (the “Conference”), in New York, New York, with a formal presentation to be made on Monday, November 5, 2007 at 12:20 p.m. Eastern time.

The Company is furnishing herewith data being presented by certain of its executive officers beginning on November 5, 2007 at the Conference. Beginning at 12:20 p.m. Eastern time on Monday November 5, 2007, an audio webcast of their remarks and accompanying graphic presentation will be made available on our website at www.encysive.com.

The Company does not undertake to update the information as posted on its website; however, it may post additional information included in future press releases and Forms 8-K, as well as posting its periodic Exchange Act reports.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

99.1 Presentation dated November 5, 2007.

[SIGNATURE PAGE FOLLOWS]

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		ENCYSIVE PHARMACEUTICALS INC.
		(Registrant)
Date: November 5, 2007
		/s/ Paul S. Manierre
		Paul S. Manierre
		Vice President, General Counsel

EXHIBIT INDEX

Exhibit No.		Description
99.1		Presentation dated November 5, 2007.

Table of Contents

Table of Contents

Table of Contents

Filing Compare · ENCYSIVE PHARMACEUTICALS INC